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ues for 7vCRM1, country-speciﬁc IPD serotype distribution
and serotype-speciﬁc immunological differences between
PHiD-CV and 7vCRM when co-administered at 6-10-14 weeks
of age with DTPw-HBV/Hib and OPV vaccines in the Philip-
pines (abstract# 3.002). SSVE’s for PHiD-CV (each serotype in
common with 7vCRM and 6A) were obtained by multiplying
7vCRM SSVE’s by the ratio of the percentages of PHiD-
CV- versus 7vCRM-vaccinated children reaching a predeﬁned
immunogenicity threshold one month after 3 primary doses.
SSVE’s for 19A (both vaccines) and for 1, 5, 7F (PHiD-CV)
were set essentially equivalent to the % children achiev-
ing the threshold for each seratype. The overall impact of
each vaccine in country-j (IPD-IEoverallj) is shown in equation
1 below.
Results: Using the 0.2g/mL threshold (22F-ELISA) as
basis of comparison and applying the IPD-IE to IPD serotype
data from several countries, PHiD-CV is estimated to pre-
vent approximately 59—85% of IPD while 7vCRM would
prevent 36—75% as shown in table below. Similar results
were obtained using ELISA 0.35g/mL or OPA 1:8 as immuno-
logical thresholds for comparison. Since countries might be
using different immunization schedules or DTPa-based co-
administered vaccines; IPD-IEs were also computed using
immunogenicity data from a European study in which
PHiD-CV or 7vCRM were co-administered with DTPa-HBV-
IPV +Hib-MenC at 2-4-6 months of age. Calculated IPD-IEs
(PHiD-CV: 57—80%; 7vCRM: 36—74%) were within the same
range as those mentioned above.
Conclusions: PHiD-CV would be predicted to prevent
59—85% of IPD in children depending on the relative impor-
tance of serotypes 1, 5, 7F in the above noted Middle East
and Asian countries.
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The activities of the antimalarial drugs- artesunate and
amodiaquine against intestinal helminth were evaluated in
l
c
T
e
al Presentations) e45
09 of 242 Nigerian children with uncomplicated Plasmod-
um falciparum malaria who had helminth before, during
nd after treatment with the two therapies. The chil-
ren were randomized to the standard dose regimens of
he drugs. Clinical recovery from malaria occurred in all
hildren. Helminth was detected in 102 patients (93.6%)
efore treatment and in another 7 patients (6.4%) after
reatment. The children treated with artesunate had sim-
lar pretreatment helminth ova load, signiﬁcantly shorter
alaria parasite clearance times (1.3 + 0.5 versus 2.8 + 1.8
, P = 0.0001), high total parasite reduction potential in 24 h
TPRP24h) (P = 0.0001) and lower geometric mean helminth
va load by day 14 (P = 0.012) following treatment than
hose treated with amodiaquine. However, helminth para-
ite excretion time was signiﬁcantly shorter in those treated
ith amodiaquine (P = 0.003). Kaplan-Meier survival curve
f cumulative probability of remaining helminth ova career
howed that by day 14 of follow-up, children treated with
rtesunate had signiﬁcant propensity to still carry helminth
va than in amodiaquine treated children (Log rank statistics
.67, df = 1, P = 0.03). These results suggest that both arte-
unate and amodiaquine not only clear malaria parasite, but
lso offer considerable anti-helminth activity that is more
ronounced with amodiaquine-an additional advantage for
ombination therapy.
oi:10.1016/j.ijid.2008.05.005
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Background and aim: There have been many reports
n co-infection with HIV and Tuberculosis, however, the
isease dynamics of drug-resistant Mycobacterium tubercu-
osis strains in areas of high HIV prevalence remains largely
nknown. This study aimed to investigate the population
tructure of drug-resistant strains in settings of high HIV
revalence in South Africa.
Methods: A molecular epidemiological approach (IS6110-
FLP, spoligotyping, MIRU-typing, drug-resistance genotyp-
ng, phylogenetic tree analysis) was used to study the
ynamics of drug-resistant strains in 3 settings with different
IV prevalence’s (Western Cape, Eastern Cape and a mine
n the Northern Province).
Results: Cluster analysis showed that more than 60% of
rug-resistant TB was due to the transmission of resistant
trains in the 3 study settings. A hyper transmissible drug-
esistant clone with the Beijing genotype was responsible
or the signiﬁcant increase in the number of drug-resistant
ases in the Western Cape setting over a 5 year period. Phy-
ogenetic analysis, of isolates collected in the mine setting,
oupled with contact tracing, demonstrated how MDR-
B acquired additional resistance markers (pyrazinamide,
thambutol and oﬂoxacin) in a stepwise manner despite
n excellent TB control program. This stepwise evolution
